Universal Vision Biotechnology (3218 TT): Steady Growth Continued in 1H23 Riding on Strong Demand
UVB reported double-digit growth in revenue, operating profit, and net profit in 1H23. UVB's dominant market position in Taiwan and favorable...
Universal Vision Biotechnology (3218 TT): Steady Revenue and Net Profit Growth in 2022;
UVB reported 30%+ revenue and profit growth in 2022. China reopening, secular industry tailwinds, technology superiority, and business expansion...
Universal Vision Biotechnology (3218 TT): Not Suffering from Myopia; Clear Long-Term Growth Prospect
Consistent revenue growth, scalable business model, and expertise in advanced refractive and cataract surgeries armed by cutting age medical...
Universal Vision Biotechnology (3218 TT): 2021 Revenue Growth of 28% Is Outlier Amid COVID-19 Crisis
The company’s continued double-digit revenue growth amid the pandemic enhances conviction on its business model. Its superior technology and...
No more insights